Targeting IL-33 and TSLP in Asthma: Efficacy Assessment in Humanized Mouse Models 2302202
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1238 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Yuan Tian und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are key epithelial cytokines driving allergic inflammation and asthma. IL-33/ST2 signaling activates type 2 immune responses, while TSLP functions as an upstream initiator of multiple inflammatory pathways. Both cytokines are promising therapeutic targets, with several IL-33— and TSLP-directed antibodies in development.
Methods
To enable in vivo evaluation of human-specific drug candidates, two humanized mouse models were generated: B-hIL33/hTSLP/hTSLPR, in which human IL33, TSLP, and TSLPR replace their murine genes, and B-hIL33(C), expressing only human IL-33. An ovalbumin (OVA)—induced asthma model was established in both backgrounds. Mice received anti-human IL-33 antibody monotherapy or combination therapy with anti-human TSLP. Endpoints included eosinophil counts, serum IgE, and lung histopathology (H&E).
Results
Both models were successfully validated, producing only human IL-33, TSLP, and TSLPR with complete loss of murine protein expression. In OVA-challenged mice, anti-IL-33 treatment significantly decreased eosinophil infiltration and IgE levels, with lung sections showing reduced inflammatory cell accumulation and mucus secretion. Importantly, in the triple-humanized B-hIL33/hTSLP/hTSLPR mice, dual blockade of IL-33 and TSLP produced greater suppression of airway inflammation compared with monotherapy, demonstrating additive therapeutic benefit.
Conclusion
The B-hIL33/hTSLP/hTSLPR and B-hIL33(C) humanized mouse models provide robust platforms for evaluating IL-33— and TSLP-targeted therapies. Their validated human cytokine signaling enables meaningful preclinical assessment of monoclonal or combination strategies, supporting advancement of next-generation biologics for allergic and inflammatory diseases. Funding Source N/A Topic Categories Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
Zitieren
APA
Tian, Y., Liu, C., Yang, L., Yuan, J., & Zhou, X. (2026). Targeting IL-33 and TSLP in Asthma: Efficacy Assessment in Humanized Mouse Models 2302202. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1238
Vancouver
Tian Y, Liu C, Yang L, Yuan J, Zhou X. Targeting IL-33 and TSLP in Asthma: Efficacy Assessment in Humanized Mouse Models 2302202. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1238
BibTeX
@article{Tian2026,
author = {Tian, Yuan and Liu, Chonghui and Yang, Liya and Yuan, Jiangfeng and Zhou, Xiaofei},
title = {Targeting IL-33 and TSLP in Asthma: Efficacy Assessment in Humanized Mouse Models 2302202},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1238}
}
EUVIMED